TKDA.F Takeda Pharmaceutical Company Limited

Healthcare Pharmaceuticals Frankfurt Exchange
18.90 EUR
Close of Nov 13, 2026
11.79 19.30
Market cap
EUR 60.4B
P/E
315.0x
P/B
1.42x
ROE
8.2%
Dividend yield
2.90%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is TKDA.F undervalued?

Graham number

The Graham number of Takeda Pharmaceutical Company Limited cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Takeda Pharmaceutical Company Limited fundamental analysis

No fundamental analysis for Takeda Pharmaceutical Company Limited yet.

Takeda Pharmaceutical Company Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gamm…

Full company profile